|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Slattery ML, John EM, Torres-Mejia G, et
al: Genetic variation in bone morphogenetic proteins and breast
cancer risk in hispanic and non-hispanic white women: The breast
cancer health disparities study. Int J Cancer. 132:2928–2939. 2013.
View Article : Google Scholar
|
|
3
|
Thawani JP, Wang AC, Than KD, et al: Bone
morphogenetic proteins and cancer: review of the literature.
Neurosurgery. 66:233–246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Buijs JT, Petersen M, van der Horst G, et
al: Bone morphogenetic proteins and its receptors; therapeutic
targets in cancer progression and bone metastasis? Curr Pharm.
16:1291–1300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ye S, Park BH, Song KJ, et al: In vivo
inhibition of bone morphogenetic protein-2 on breast cancer cell
growth. Spine (Phila Pa 1976). 38:E143–E150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo D, Huang J and Gong J: Bone
morphogenetic protein 4 (BMP4) is required for migration and
invasion of breast cancer. Mol Cell Biochem. 363:179–190. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lian WJ, Liu G, Liu YJ, et al:
Downregulation of BMP6 enhances cell proliferation and
chemoresistance via activation of the ERK signaling pathway in
breast cancer. Oncol Rep. 30:193–200. 2013.PubMed/NCBI
|
|
8
|
Rodriguez-Martinez A, Alarmo EL, Saarinen
L, et al: Analysis of BMP4 and BMP7 signaling in breast cancer
cells unveils time-dependent transcription patterns and highlights
a common synexpression group of genes. BMC Med Genomics. 4:802011.
View Article : Google Scholar
|
|
9
|
Wang K, Feng H, Ren W, et al: BMP9
inhibits the proliferation and invasiveness of breast cancer cells
MDA-MB-231. J Cancer Res Clin Oncol. 137:1687–1696. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ye L, Bokobza S, Li J, et al: Bone
morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast
cancer cells and correlates with poor prognosis in breast cancer.
Cancer Sci. 101:2137–2144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
You JS and Jones PA: Cancer genetics and
epigenetics: two sides of the same coin? Cancer Cell. 22:9–20.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanwal R and Gupta S: Epigenetic
modifications in cancer. Clin Genet. 81:303–311. 2012. View Article : Google Scholar
|
|
13
|
Wen XZ, Akiyama Y, Baylin SB, et al:
Frequent epigenetic silencing of the bone morphogenetic protein 2
gene through methylation in gastric carcinomas. Oncogene.
25:2666–2673. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fu B, Wang H, Wang J, et al: Epigenetic
regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA
methylation and histone modification. PLoS One. 8:e614232013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
|
|
16
|
Alarmo EL, Kuukasjärvi T, Karhu R, et al:
A comprehensive expression survey of bone morphogenetic proteins in
breast cancer highlights the importance of BMP4 and BMP7. Breast
Cancer Res Treat. 103:239–246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Davies SR, Watkins G, Douglas-Jones A, et
al: Bone morphogenetic proteins 1 to 7 in human breast cancer,
expression pattern and clinical/prognostic relevance. J Exp Ther
Oncol. 7:327–338. 2008.PubMed/NCBI
|
|
18
|
Ghosh-Choudhury N, Ghosh-Choudhury G,
Celeste A, et al: Bone morphogenetic protein-2 induces cyclin
kinase inhibitor p21 and hypophosphorylation of retinoblastoma
protein in estradiol-treated MCF-7 human breast cancer cells.
Biochim Biophys Acta. 1497:186–196. 2000. View Article : Google Scholar
|
|
19
|
Waite KA and Eng C: BMP2 exposure results
in decreased PTEN protein degradation and increased PTEN levels.
Hum Mol Genet. 12:679–684. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Clement JH, Raida M, Sänger J, et al: Bone
morphogenetic protein 2 (BMP-2) induces in vitro invasion and in
vivo hormone independent growth of breast carcinoma cells. Int J
Oncol. 27:401–407. 2005.PubMed/NCBI
|
|
21
|
Raida M, Clement JH, Leek RD, et al: Bone
morphogenetic protein 2 (BMP-2) and induction of tumor
angiogenesis. J Cancer Res Clin Oncol. 131:741–750. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jones PA: Functions of DNA methylation:
islands, start sites, gene bodies and beyond. Nat Rev Genet.
13:484–492. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Carvalho DD, Sharma S, You JS, et al:
DNA methylation screening identifies driver epigenetic events of
cancer cell survival. Cancer Cell. 21:655–667. 2012.PubMed/NCBI
|
|
24
|
Hervouet E, Cartron PF, Jouvenot M, et al:
Epigenetic regulation of estrogen signaling in breast cancer.
Epigenetics. 8:237–245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pang JM, Dobrovic A and Fox SB: DNA
methylation in ductal carcinoma in situ of the breast. Breast
Cancer Res. 15:2062013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Connolly R and Stearns V: Epigenetics as a
therapeutic target in breast cancer. J Mammary Gland Biol
Neoplasia. 17:191–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dagdemir A, Durif J, Ngollo M, et al:
Breast cancer: mechanisms involved in action of phytoestrogens and
epigenetic changes. In Vivo. 27:1–9. 2013.PubMed/NCBI
|
|
28
|
Huang Y, Nayak S, Jankowitz R, et al:
Epigenetics in breast cancer: what’s new? Breast Cancer Res.
13:2252011.
|
